Clavulanic acid and avibactam are clinically deployed serine b-lactamase inhibitors, important as a defence against antibacterial resistance. Bicyclic boronates are recently discovered inhibitors of serine and some metallo b-lactamases. Here, we show that avibactam and a bicyclic boronate inhibit L2 (serine b-lactamase) but not L1 (metallo b-lactamase) from the extensively drug resistant human pathogen Stenotrophomonas maltophilia. X-ray crystallography revealed that both inhibitors bind L2 by covalent attachment to the nucleophilic serine. Both inhibitors reverse ceftazidime resistance in S. maltophilia because, unlike clavulanic acid, they do not induce L1 production.
Introduction
b-Lactamases are the most commonly encountered cause of resistance to b-lactams, which are the most frequently prescribed class of antibacterial drug worldwide (Hamad, 2010; Van Boeckel et al., 2014; Versporten et al., 2014) . b-Lactamases render blactams inactive through catalysing efficient hydrolysis of the b-lactam ring (Strynadka et al., 1992; Drawz and Bonomo, 2010) . There are many hundreds of known blactamases, which are grouped based on sequence and mechanism into the serine b-lactamase (SBL) classes A, C and D, and the metallo-b-lactamase (MBL) subclasses B1, B2 and B3) (Ambler, 1980; Bush, 2013) . Broad-spectrum, clinically useful b-lactamase inhibitors are being sought, but the varying chemistries and active site architectures of the different b-lactamase classes makes the development of crossclass inhibitors extremely challenging (Drawz et al., 2014; Brem et al., 2016; King et al., 2016) .
Clavulanic acid (Fig. 1, top) is a well-established clinically deployed b-lactam-based inhibitor of, principally, class A SBLs. Clavulanic acid is used in combination with penicillin derivatives such as amoxicillin and ticarcillin, whose bactericidal effects improve against some b-lactamase-carrying isolates of species such as Escherichia coli and Klebsiella pneumoniae (Reading and Cole, 1977; Al Roomi et al., 1984; Fass and Prior, 1989; Finlay et al., 2003) . Clavulanic acid is an irreversible inhibitor of class A enzymes, whose activity arises from fragmentation of the acyl-enzyme complex formed by reaction with the active-site serine nucleophile, to generate a near permanently inactivated species (Sulton et al., 2005) . In contrast, avibactam, a recently introduced relatively broad spectrum non-b-lactam-based SBL inhibitor contains a diazobicyclo heterocyclic core structure which reversibly acylates SBLs. The potency of avibactam against class A, C and some class D SBLs is attributed to the stabilization of the carbamoyl complex due to interactions with polar residues present in the active sites, with deacylation preferentially occurring due to recyclization rather than hydrolytic turnover (Ehmann et al., 2012) . This recyclization results in release of intact active inhibitor rather than an inactive hydrolysis product (Fig. 1, middle) (Stachyra et al., 2010; Coleman, 2011; Choi et al., 2016; Wang et al., 2016) . Avibactam has recently been licenced for clinical use in partnership with the oxy-amino cephalosporin ceftazidime, although the combination is not universally efficacious and has no useful activity against MBLproducing bacteria (Coleman, 2011; Abboud et al., 2016) .
Boronic acid-based compounds have long been studied as potential SBL inhibitors but, in most cases, are ineffective against MBL targets. For example, the monocyclic boronate vaborbactam (RPX7009; Fig. 1 , bottom left), which has recently been approved for clinical use, is effective against Class A, C and D b-lactamases, but not MBLs (Hecker et al., 2015) . However, we recently demonstrated that bicyclic boronate scaffolds can act as potent inhibitors of multiple SBL classes, as well as subclass B1 MBLs . Accordingly, one method of overcoming the poor activity of ceftazidime/ avibactam against MBL producing bacteria would be to combine ceftazidime with a bicyclic boronate inhibitor, such as 2 (Fig. 1, bottom right) , or 1, which is derived from the same scaffold (Cahill et al., 2017) . Together, 1 and 2 represent the closest approach to a pan-blactamase inhibitor that has, to-date, been reported in the literature (Cahill et al., 2017) . Another bicyclic boronate b-lactamase inhibitor (VNRX-5133) has recently completed phase 1 clinical trials (ClinicalTrials.gov, 2016) .
Stenotrophomonas maltophilia (Ryan et al., 2009 ) is one of the most intrinsically multidrug resistant bacterial species encountered in the clinic, causing up to 5% of ventilator associated pneumonias, and around 1% of blood-stream infections. It causes serious infections with high mortality rates in immunocompromised and severely debilitated patients, and colonises the lungs of 20-30% of patients with cystic fibrosis (Looney et al., 2009; de Vrankrijker et al., 2010; Brooke, 2012) . While S. maltophilia possesses multiple efflux systems (Alonso and Martinez, 2000; Gould et al., 2013; Garcia-Leon et al., 2015) that reduce the net rate of entry for many antimicrobials, b-lactam resistance arises primarily from production of two blactamases, a subclass B3 MBL 'L1', which hydrolyses all b-lactams except for the monobactam, aztreonam and the class A Extended Spectrum SBL (ESBL) 'L2', which hydrolyses all first to third generation cephalosporins, all penicillins and aztreonam (Walsh et al., 1994 (Walsh et al., , 1997 . The combination of L1 and L2, therefore, renders S. maltophilia resistant to all blactam antibiotics although in clinical practice, ceftazidime can be useful, because most clinical isolates do not produce enough b-lactamase to give resistance (Lemmen et al., 2001; Okazaki and Avison, 2008) . Ceftazidime resistant mutants rapidly emerge through hyperproduction of L1 and L2, via single site mutations that directly or indirectly activate the L1/L2 transcriptional activator, AmpR (Okazaki and Avison, 2008; Talfan et al., 2013) . Accordingly, S. maltophilia represents one of the most challenging targets for b-lactam/ b-lactamase inhibitor combinations.
Here, we report kinetic and structural studies with purified S. maltophilia b-lactamases, in vitro testing of various b-lactam/b-lactamase inhibitor combinations against extensively drug resistant clinical S. maltophilia isolates, and characterisation of acquired resistance to 
Results
b-lactamase inhibitors restore aztreonam, but not meropenem activity against S. maltophilia As a prelude to investigating the effects of b-lactamase inhibitors, we first evaluated the hydrolysis of a range of candidate b-lactams in vitro by purified L1 (subclass B3 MBL) and L2 (class A ESBL) under steady state conditions. These data (Table 1) reveal the carbapenem meropenem to be predominantly a substrate for L1, with L2 showing only weak hydrolytic activity, the monobactam aztreonam to be a substrate for L2 only and that both L1 and L2 can hydrolyse the oxyamino-cephalosporin ceftazidime with similar efficiencies.
We next tested the ability of three b-lactamase inhibitors: clavulanic acid, avibactam and the bicyclic boronate 2 (each at 2 mg.L 21 ) to potentiate the activity of the target b-lactams against S. maltophilia ( (Talfan et al., 2013) . Interestingly, all three inhibitors were unable to restore ceftazidime susceptibility in a ceftazidime resistant L1/L2 hyperproducing clinical isolate (CI-31), but they all restored aztreonam susceptibility in CI-31 (Table 2) . Efflux pumps play a major role in antimicrobial resistance in S. maltophilia (Crossman et al., 2008; Brooke, 2012) . Thus, to investigate the possible effect of multidrug efflux pumps on b-lactamase inhibitor efficacy, we selected two hyper-resistant mutants from the isolate K279a using moxifloxacin and amikacin, known to be efflux pump substrates. Comparative proteomics (Supporting Information Tables S1 and S2, Fig. S1 ) confirmed that the two mutants, K MOX 8 and K AMI 32, hyperproduce the SmeDEF and SmeYZ efflux pumps, respectively. In K MOX 8, SmeYZ was downregulated as SmeDEF was hyperproduced, as expected given their reciprocal regulation (Huang et al., 2017) . All three b-lactamase inhibitors retained full activity against these efflux pump hyperproducing mutants (Table 2) suggesting that efflux does not have a major role in the observed variation in efficacy of the various b-lactam/ b-lactamase inhibitor combinations.
The bicyclic boronate 2 does not inhibit the S. maltophilia L1 MBL
Based on these in vitro data we conclude that the bicyclic boronate 2 acts against S. maltophilia in a similar fashion to avibactam and clavulanic acid: it reverses aztreonam and, when due to L1/L2 hyperproduction, ceftazidime resistance ( Table 2 ). As 2 has been shown to inhibit multiple MBLs , we anticipated that it might also inhibit L1, but the fact that 2 does not reverse resistance to meropenem (Table 2) , which is predominantly hydrolysed by L1 (Table 1) suggests that L1 inhibition by 2 does not occur to a significant extent. As, to date, the inhibition of subclass B3 MBLs by bicyclic boronates has not been reported, we investigated the inhibition of purified L1 and L2 by the three blactamase inhibitors using the fluorogenic b-lactamase substrate FC5 as a new reporter for L1 and L2 (van Berkel et al., 2013) . Calculated k cat /K M values clearly demonstrate that FC5 is hydrolysed with a higher efficiency than other b-lactams by both L1 and L2 (Table  1) . IC 50 measurements revealed that while all three blactamase inhibitors inhibit L2 with nanomolar potencies (Table 3) , no inhibition of L1 was observed, even when using inhibitor concentrations up to 2.5 mM. NMR spectroscopy confirmed that there is no impact of avibactam or 2 on meropenem hydrolysis by L1 (Supporting Information Fig. S2 ). NMR experiments also showed that L1 can hydrolyse avibactam, albeit at a slow rate, but it does not modify 2 to any detectable extent following incubation up to 24 h (Supporting Information Fig. S3 ). Thus, unlike the case for subclass B1 MBLs , the bicyclic boronate 2 is not an effective inhibitor of the subclass B3 MBL L1.
Structural basis for inhibition of L2 by avibactam and the bicyclic boronate 2
The results above demonstrate that, consistent with the effectiveness of b-lactam/b-lactamase inhibitor combinations against S. maltophilia strains, L2 is effectively inhibited by both avibactam and the bicyclic boronate 2. To investigate the molecular basis for inhibition of L2 we crystallised the enzyme and soaked the crystals in avibactam or 2. Consistent with our inhibition kinetics results, we were unable to obtain crystal structures of complexes of L1 with either of these inhibitors. L2 crystallised in the space group P2 1 2 1 2 1 with two molecules in the asymmetric unit (Supporting Information Table  S3 ), and closely conserves the overall SBL fold with, for example, an RMSD to KPC-2 (PDB 2OV5) of 0.2 Å . L2 crystals formed in a reagent containing a 0.1 M racemic mixture of the amino acids glutamate, alanine, lysine and serine. The active site manifests clear F o -F c density into which a molecule of D-glutamate could be modelled (Supporting Information Fig. S4A ), indicating the Denantiomer preferentially binds to L2. However, binding does not perturb the active site conformation compared with an uncomplexed L2 crystal structure (PDB 1O7E; Supporting Information Fig. S5 ), preserving positioning of the hydrolytic (deacylating) water with respect to Glu166, Asn170 and Ser70 (see Supporting Information  Table S4 for distances), and the conformation of the conserved, catalytically important Lys73 (Meroueh et al., 2005; Fonseca et al., 2012; Vandavasi et al., 2016) . D-glutamate binds noncovalently, through interactions of its carbonyl oxygen with the backbone amides in the oxyanion hole (formed by residues Ser70 and Ser237), the C-terminal oxygen with Ser130-Og and the glutamate amide with the deacylating water ( Fig. 2A ). Despite these extensive interactions, there is little inhibitory effect, with 100 mM D-glutamate reducing L2 activity by just 20% (Supporting Information Fig. S6 ), indicating binding is weak and the ligand can be easily displaced by substrate. The presence of D-glutamate in the active site of our L2 crystal structure is, therefore, a crystallisation artefact and is due to the excess of amino acid in the crystallisation buffer. D-glutamate binds differently compared with the high affinity binding (K i 5 84 pM) of the b-lactamase inhibitory protein (BLIP) to the class A b-lactamase KPC-2 (PDB 3E2K). Interestingly, BLIP binding to KPC-2 involves localisations of an Laspartate residues at the active site, in a manner related to, but different from, D-glutamate binding to L2, and one that does not involve interactions with the oxyanion hole (Supporting Information Fig. S7 ) (Hanes et al., 2009) .
L2:avibactam and L2:bicyclic boronate 2 co-complex structures were solved to 1.35 Å and 2.09 Å resolution, respectively, with clear F o -F c density indicating both inhibitors form a covalent attachment to the active site nucleophile Ser70 (Supporting Information Fig. S4B and S4C). Binding by both compounds reveals no significant changes in the L2 active site in comparison with the apo or D-glutamate structures. Indeed, in both structures the b-lactamase inhibitors versus S. maltophilia 495 deacylating water is positioned similarly to the native and D-glutamate-bound structures (Supporting Information Table S4 ). The bicyclic boronate 2 binds covalently to Ser70 of L2 ( Fig. 2B) with the boron atom clearly in a tetrahedral geometry. This is also observed previously on binding of the closely related bicyclic boronate 1 to CTX-M-15 (another class A ESBL) (Cahill et al., 2017) and OXA-10 (a class D SBL) . Hence, bicyclic boronates bind SBLs in a form that mimics the first tetrahedral intermediate formed during b-lactam hydrolysis, which is involved in acyl-enzyme formation, rather than mimicking the acyl-enzyme itself, that is, these inhibitors are 'transition state analogues'. As in D-glutamate binding, the assigned OH group on the boron atom is positioned to make strong interactions with the backbone amides of Ser70 (2.95 Å ) and Ser237 (3.1 Å ) in the oxyanion hole. The bicyclic boronate 2 makes additional hydrogen bonds to the side chains of the catalytically important residues Ser130 (2.77 Å to the bicyclic ring oxygen), Asn132 (3.0 Å to the benzamide oxygen), Ser237 (2.96 Å to the carboxylate) Thr235 (2.65 Å to the carboxylate) and the backbone carbonyl oxygen of Ser237 (3.1 Å to the benzamide nitrogen). In addition, binding is stabilised by significant hydrophobic interactions with His105.
Avibactam (Fig. 2C ) binds to L2 in its ring opened form, forming a carbamoyl-enzyme complex (Ehmann et al., 2012) in which its six-membered ring is in a chair conformation, a conserved feature in other structurally characterised avibactam:b-lactamase complexes (Xu et al., 2012; Lahiri et al., 2013 Lahiri et al., , 2014 Lahiri et al., , 2015 Krishnan et al., 2015; King et al., 2015) . Highlighting the importance of the oxyanion hole, as with both D-glutamate and the bicyclic boronate 2, the avibactam-derived carbamoyl oxygen is positioned to make hydrogen bonds with the oxyanion hole backbone amides of Ser70 (2.75 Å ) and Ser237 (2.85 Å ). His105 is also involved in providing stabilising hydrophobic interactions (3.49 Å ), while the carbamoyl NH interacts with the backbone carbonyl of Ser237 (3.08 Å ) and the Asn132 sidechain (2.97 Å ). The carbamoyl NH interactions may be relatively less important as they present in only one molecule in the asymmetric unit (chain B). The avibactam sulfate moiety interacts with the OH groups of both Thr235 (3.10 Å ) and Ser130 (2.88 Å ), with an additional 3.19 Å interaction with Ser237 in chain B.
b-Lactamase production is not induced by avibactam and the bicyclic boronate 2
One important consideration when deploying blactamase inhibitors into clinical practice is that some can interact with penicillin binding proteins and trigger b-lactamase induction pathways carried by many bacteria. L1 and L2 production in S. maltophilia is controlled by a transcriptional regulator, AmpR, which is responsive to b-lactam challenge via sensing b-lactam mediated perturbations in peptidoglycan breakdown and recycling (Jacobs et al., 1994 (Jacobs et al., , 1997 ). Hence, we tested the ability of b-lactamase inhibitors to induce blactamase production in S. maltophilia. Clavulanic acid induces L1 production (measured using meropenem hydrolysis in cell extracts) at a similar level to the positive control b-lactam cefoxitin in the S. maltophilia wildtype strain K279a (Fig. 3) . This observation rationalizes why clavulanic acid does not reduce the MIC of ceftazidime against S. maltophilia K279a ( Table 2) : induction of L1 (Fig. 3) overcomes inhibition of L2 (Table 3) because L1 can hydrolyse ceftazidime (Table 1 ). Since Interactions between residues and the catalytic water are shown as red dashes, and interactions between residues and ligand as blue dashes. Labelled residues are those that specifically interact with the ligand.
L1 does not hydrolyse aztreonam (Table 1) , however, clavulanic acid reduces the aztreonam MIC against K279a, despite its ability to induce L1 production (Table 2, Fig. 3) . Notably, by contrast with clavulanic acid, both avibactam and the bicyclic boronate 2 reduce ceftazidime MICs against K279a (Table 2 ). This observation is explained by the important finding that neither avibactam nor 2 induces L1 to any measurable extent (Fig. 3 ), yet both inhibit L2 (Table 3) . Selection and characterisation of mutants which overcome the reversal of ceftazidime resistance by avibactam and the bicyclic boronate 2
Avibactam is currently only clinically available in combination with ceftazidime. The fact that L1 induction by clavulanic acid overcomes its ability to reduce ceftazidime MICs against S. maltophilia (Fig. 3, Table 2 ) led us to suggest that L1/L2 hyperproducing, ceftazidime resistant strains might further mutate to be ceftazidime resistant in the presence of avibactam and the bicyclic boronate 2 by producing even more L1. To investigate this possibility, we used a K279a ampR mutant, M11, which is ceftazidime resistant due to L1/L2 hyperproduction but where ceftazidime resistance can be reversed following treatment with avibactam or 2 at 10 mg.L 21 (Table 4) . We aimed to identify mutants able to grow on ceftazidime at >32 mg.L 21 (i.e., clinically resistant, according to CLSI breakpoints (CLSI, 2015) ) in the presence of either avibactam or 2 at 10 mg.L
21
. Mutants were readily obtained; those selected using ceftazidime/avibactam were also resistant to ceftazidime/2, and vice versa (Table 4) . To investigate the basis for resistance, LC-MS/ MS proteomics was used to quantify changes in protein production in the two mutants. In both cases, L1 was produced at levels $threefold greater than in the parent strain (Supporting Information Tables S5 and S6 , Fig. 4A ). This result was confirmed by measuring L1 enzyme activity in cell extracts using meropenem as substrate (Fig. 4B) . Thus, hyperproduction of L1 can overcome the ability of these L2-specific inhibitors to rescue ceftazidime activity against a ceftazidime-resistant strain. Importantly, however, the mutants were still sensitive to the aztreonam/avibactam or aztreonam/2 combinations (Table 4) as L1 cannot hydrolyse aztreonam ( Table 1) . The L1 hyperproducing phenotype, blocking reversal of ceftazidime, but not aztreonam, resistance by blactamase inhibitors is clearly relevant, because it is displayed by clinical isolate CI-31 (Table 2 ).
Discussion
Our structural data reveal that the bicyclic boronate 2 binds to the ESBL L2 in a manner similar to that previously observed for the closely related bicyclic boronate 1 binding to the ESBL CTX-M-15. For the bicyclic boronate 2, binding of the tetrahedral boron atom to L2 and conformation of the bicyclic fused core are all consistent with the CTX-M-15:bicyclic boronate 1 structure (Cahill et al., 2017) ; there is only slight variation in the amide/ benzamide side chain conformations (Fig. 5A) . Furthermore, formation of the L2 carbamoyl-enzyme complex by avibactam results in a conformationally similar mode of binding compared with structurally characterised complexes with the class A SBLs KPC-2 (PDB 4ZBE) (Krishnan et al., 2015) , SHV-1 (PDB 4ZAM) (Krishnan et al., 2015) and CTX-M-15 (PDB 4S2I) (King et al., 2015) (Fig. 5B) , and is consistent with data indicating maltophilia K279a. S. maltophilia isolate K279a was incubated in presence of different potential inducers (cefoxitin, clavulanic acid, the bicyclic boronate 2, or avibactam) at 50 mg.L 21 ). L1 activity was measured from the cell extracts in a 96-well plate reader by determining meropenem hydrolysis (100 mM) at k 5 300 nm. Protein concentration was determined by using the BioRad protein assay dye reagent. Specific activity was calculated by using the extinction coefficient of 9600 AU.M
21
.cm 21 and a pathlength correction for the microplate (0.62 cm). Data presented are means 6 SEM, n 5 3.
b-lactamase inhibitors versus S. maltophilia 497 avibactam to be similarly effective against these enzymes (Stachyra et al., 2009; Ehmann et al., 2012; Krishnan et al., 2015) . However, some subtle differences in active-site interactions are observed (Supporting Information Fig. S8 ). In particular, while the avibactam carbamoyl hydrogen bond with Asn132 is conserved, the weaker carbamoyl interaction with the carbonyl oxygen of L2-Ser237 is not, highlighting that such an interaction is not essential for binding. Furthermore, the avibactam sulfate moiety interaction with Thr235 is likely important as it presents in all SBLs, while interaction with Ser130 is present in KPC-2 alone. In SHV-1:avibactam, interaction of the sulfate group with the nonconserved Arg244 essentially substitutes for the sulfateSer237 interaction in other SBLs (Thr237 in KPC-2). In both SHV-1:avibactam and KPC-2:avibactam the 'hydrolytic' deacylating water molecule hydrogen bonds to the avibactam carbamoyl, while this interaction is not observed with either CTX-M-15:avibactam or L2:avibactam. The avibactam-derived sulfate-bonded nitrogen is in the same conformation as in KPC-2/SHV-1:avibactam and, unlike in the CTX-M-15:avibactam complex, is directed away from the six-membered ring and distant from Ser130 (Ser130, 3.57 Å ) (King et al., 2015) and consequently is not primed for re-cyclization (Choi et al., 2016) in which this residue is involved (Fig. 5B) . The CTX-M-15:avibactam complex therefore remains to date as the only crystallographic evidence for avibactam reacting with an SBL in a conformation ideal for recyclization (King et al., 2015) . Thus, the rate at which the avibactam-derived complex can recyclize to reform intact avibactam may vary between SBLs.
Even though our structural and kinetic work confirm that L2 is potently inhibited by avibactam and the bicyclic boronate 2, we predicted failure of avibactam/ceftazidime against S. maltophilia. Our prediction was based on the observation that L1-hyperproducing mutants are readily obtained from S. maltophilia isolates (Fig. 4) , and avibactam does not inhibit MBLs . While 2 inhibits subclass B1 MBLs , our work reveals that it does not inhibit the subclass B3 MBL, L1 (Table 3 , Supporting Information Fig. S2 ) and so 2/ceftazidime was also overcome by L1 hyperproduction (Table 4 , Fig. 4) . It may be possible to modify 2 and so generate a broader-spectrum MBL inhibitor. However, a key finding of this work is that such a modification might not be essential. Avibactam and 2 both facilitate killing of S. maltophilia when paired with the monobactam, aztreonam, reducing MICs to 4 mg.L 21 even in the pan-resistant clinical S.
maltophilia isolate, CI-31 (Table 2 ). These data imply that aztreonam/avibactam and aztreonam/2 may have a promising clinical future for treatment of infections caused by this most intractable of species. The fact that efflux pump over-production does not affect aztreonam/2 or aztreonam/avibactam activity (Table 2) gives even greater cause In (A), L1 protein abundance data (relative to mean ribosomal protein abundance for each sample). Full proteomics data are shown in Supporting Information Tables S5 and S6 . In (B), L1 enzyme activity in cell extracts is reported as meropenem hydrolysis rate. Data are reported as mean 6 SEM, n 5 3 for the parent strain, M11 and the two mutants (MB25 and MA27), which are resistant to ceftazidime/avibactam and ceftazidime/2.
for optimism. We were interested to read, therefore, a recent clinical case report demonstrating the use of combination therapy with ceftazidime/avibactam plus aztreonam to save the life of a patient with an S. maltophilia infection that had failed all prior therapy (Mojica et al., 2016) . Our structural, kinetic and whole bacterial killing data would lead to the conclusion that ceftazidime was probably superfluous in this success, but our work indicates that ceftazidime/avibactam plus aztreonam might be routinely considered in the clinic for use against seemingly untreatable S. maltophilia infections while aztreonam/avibactam works its way through the clinical trials system. Positive results have been seen with ceftazidime/avibactam plus aztreonam against Enterobacteriaceae isolates carrying multiple b-lactamases, but the combination was not universally efficacious (Marshall et al., 2017) . In many respects, because of its inability to inhibit L1, the bicyclic boronate 2 acts against S. maltophilia very similarly to avibactam. One potentially significant difference is that avibactam is hydrolysed by L1, but 2 retains its structural integrity (Supporting Information Fig. S3 ). This hydrolysis is slow, and even if L1 is hyperproduced, it is not significant enough to confer aztreonam/avibactam resistance (Table 4) . However, there is a chance that L1 mutants might be selected with greater avibactam hydrolytic activity, reducing the degree of L2 inhibition and raising the MIC of aztreonam/avibactam into the resistant range. This observation may also be of relevance to other avibactam-like compounds in development, for example, Relebactam (Blizzard et al., 2014) . In contrast, given that modification of 2 in the presence of wild-type L1 is undetectably slow, evolution to increased breakdown may require significantly more steps, potentially increasing the long-term efficacy of aztreonam/2 as a combination to treat S. maltophilia infections.
In conclusion, our combined results reveal the potential of nonclassical non b-lactam containing b-lactamase inhibitors, including the clinically approved compound avibactam, and the cyclic boronates (some of which are presently in clinical trials) for treatment of S. maltophilia, particularly when partnered with the monobactam aztreonam, and perhaps other aztreonam-like b-lactams currently in development. Given the structural differences between avibactam, cyclic boronates and the b-lactam-based inhibitors, it would seem that there is considerable scope for the identification of new types of b-lactamase inhibitors of potential clinical utility against Gram-negative bacterial pathogens.
Experimental procedures
Bacterial isolates and materials S. maltophilia clinical isolates were K279a, a well characterised isolate from Bristol, UK, or were obtained from the SENTRY antimicrobial resistance survey, as previously reported . The ceftazidime resistant, blactamase hyperproducing K279a-derived mutants used were K CAZ 10 ( Talfan et al., 2013) and K M11 (Okazaki and Avison, 2008) . Efflux-pump over-producing mutants K AMI 32 and K MOX 8 were selected using K279a as parent strain as previously described . All growth media were from Oxoid. Chemicals were from Sigma, unless otherwise stated. Avibactam was from AstraZeneca while bicyclic boronate 2 was synthesised according to published protocols (Burns et al., 2010) .
Assay of b-lactamase activity in cell extracts, b-lactamase induction and b-lactam susceptibility Cultures were grown overnight using nutrient broth and used to inoculate (1:100 dilution) 10 mL nutrient broth cultures in sealed 30 mL universal bottles. Cultures were incubated for 2 h with shaking at 378C before test inducers were added, or not, and culture was continued for 2 h. Cells were pelleted by centrifugation (4,000g, 10 min) and pellets treated with 100 mL of BugBuster (Ambion), pipetting up and down a few times before rocking for 10 min at room temperature. Cell debris and unlysed cells were pelleted by centrifugation (13,000g, 5 min) and the supernatant retained as a source of crude cell protein. Protein concentrations were determined using the BioRad protein assay reagent concentrate according to the manufacturer's instructions. L1 b-lactamase activity was determined using an Omega Fluostar (BMG Biotech) using meropenem as substrate in half-area 96 well UV-translucent plates (Greiner UV-Star. Bio-one) with 200 mL of 100 mM meropenem solution in assay buffer (60 mM Na 2 HPO 4 Á7H 2 O pH 7.0, 40 mM NaH 2 PO 4 ÁH 2 O, 10 mM KCl, 1 mM MgSO 4 Á7H 2 O, 100 mM ZnCl 2 ) plus 10 mL of cell extract. Substrate depletion was followed at 300 nm for 10 mins and an extinction coefficient of 9600 AU.M
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.cm 21 was used to calculate enzyme activity in the linear phase of the reaction.
Susceptibility to b-lactams in bacterial isolates was determined using the CLSI microtitre MIC methodology with Muller-Hinton Broth using 96 well plates (Corning, Costar). The MIC was determined as the lowest concentration of blactam required to entirely suppress growth (CLSI, 2015) . Inhibitor concentrations were kept constant at 2 mg.L 21 or 10 mg.L 21 in all assays. Interpretation of susceptibility/ resistance was by reference to CLSI clinical breakpoints for S. maltophilia (ceftazidime) and for Pseudomonas aeruginosa (for aztreonam and meropenem, since no S. maltophilia breakpoints are available) (CLSI, 2015) .
Proteomic analysis
Cells in 50 mL nutrient broth cultures were pelleted by centrifugation (10 min, 4,000g, 48C) and resuspended in 20 mL of 30 mM Tris-HCl, pH 8 and broken by sonication using a cycle of 1 s on, 0.5 s off for 3 min at amplitude of 63% using a Sonics Vibracell VC-505TM (Sonics and Materials Inc., Newton, Connecticut). The sonicated samples were centrifuged at 8,000 r.p.m. (Sorval RC5B PLUS using an SS-34 rotor) for 15 min at 48C to pellet intact cells and b-lactamase inhibitors versus S. maltophilia 499 large cell debris; the supernatant was removed and concentrated (Amicon 3 kDa cutoff filter) for analysis of total cell protein. Alternatively, for envelope preparations, the supernatant was not concentrated, and instead, subjected to centrifugation at 20,000 r.p.m. for 60 min at 48C using the above rotor to pellet total envelopes. To isolate total envelope proteins, this total envelope pellet was solubilised using 200 lL of 30 mM Tris-HCl pH 8 containing 0.5% (w/v) SDS.
Protein concentrations in all samples was quantified using Biorad Protein Assay Dye Reagent Concentrate according to the manufacturer's instructions. Proteins (2.5 lg/Lane for total cell proteomics or 5 mg/Lane for envelope protein analysis) were separated by SDS-PAGE using 11% acrylamide, 0.5% bis-acrylamide (Biorad) gels and a Biorad Min-Protein Tetracell chamber model 3000X1. Gels were resolved at 200 V until the dye front had moved approximately 1 cm into the separating gel. Proteins in all gels were stained with Instant Blue (Expedeon) for 20 min and destained in water.
The 1 cm of gel lane was subjected to in-gel tryptic digestion using a DigestPro automated digestion unit (Intavis Ltd). The resulting peptides from each gel fragment were fractionated separately using an Ultimate 3000 nanoHPLC system in line with an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). In brief, peptides in 1% (v/v) formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After washing with 0.5% (v/v) acetonitrile plus 0.1% (v/v) formic acid, peptides were resolved on a 250 mm 3 75 lm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 150 min organic gradient, using seven gradient segments (1-6% solvent B over 1 min., 6-15% B over 58 min., 15-32% B over 58 min., 32-40% B over 5 min., 40-90% B over 1 min., held at 90% B for 6 min and then reduced to 1% B over 1 min.) with a flow rate of 300 nL/min. Solvent A was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid. Peptides were ionized by nano-electrospray ionization MS at 2.1 kV using a stainless-steel emitter with an internal diameter of 30 lm (Thermo Scientific) and a capillary temperature of 2508C. Tandem mass spectra were acquired using an LTQOrbitrap Velos mass spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific) and operated in datadependent acquisition mode. The Orbitrap was set to analyze the survey scans at 60,000 resolution (at m/z 400) in the mass range m/z 300 to 2000 and the top twenty multiply charged ions in each duty cycle selected for MS/MS in the LTQ linear ion trap. Charge state filtering, where unassigned precursor ions were not selected for fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30 s; exclusion list size, 500) were used. Fragmentation conditions in the LTQ were as follows: normalized collision energy, 40%; activation q, 0.25; activation time 10 ms; and minimum ion selection intensity, 500 counts.
The raw data files were processed and quantified using Proteome Discoverer software v1.4 (Thermo Scientific) and searched against the UniProt S. maltophilia strain K279a database (4365 protein entries; UniProt accession UP000008840) using the SEQUEST (Ver. 28 Rev. 13) algorithm. Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was set at 0.8 Da. Search criteria included carbamidomethylation of cysteine (157.0214) as a fixed modification and oxidation of methionine (115.9949) as a variable modification. Searches were performed with full tryptic digestion and a maximum of 1 missed cleavage was allowed. The reverse database search option was enabled and all peptide data was filtered to satisfy false discovery rate (FDR) of 5%. The Proteome Discoverer software generates a reverse 'decoy' database from the same protein database used for the analysis and any peptides passing the initial filtering parameters that were derived from this decoy database are defined as false positive identifications. The minimum crosscorrelation factor filter was readjusted for each individual charge state separately to optimally meet the predetermined target FDR of 5% based on the number of random false positive matches from the reverse decoy database. Thus, each data set has its own passing parameters. Protein abundance measurements were calculated from peptide peak areas using the Top 3 method (Silva et al., 2006) and proteins with fewer than three peptides identified were excluded. The proteomic analysis was repeated three times for each parent and mutant strain, each using a separate batch of cells. Data analysis was as follows: all raw protein abundance data were uploaded into Microsoft Excel. Raw data from each sample were normalised by division by the average abundance of all 30S and 50S ribosomal protein in that sample. A one-tailed, unpaired T-test was used to calculate the significance of any difference in normalised protein abundance data in the three sets of data from the parent strains versus the three sets of data from the mutant derivative. A p-value of <0.05 was considered significant. The fold change in abundance for each protein in the mutant compared to its parent was calculated using the averages of normalised protein abundance data for the three biological replicates for each strain. All raw protein abundance data are provided in the attached proteomics data file.
Purification of L1 and L2 and kinetics assays
Recombinant L1 and L2 proteins were produced in E. coli and purified as previously described (Calvopina et al., 2016) . Enzyme activity was monitored using an Omega Fluostar (BMG Labtech) using buffer L1 (50 mM HEPES pH 7.5, 10 mg.mL 21 BSA, 10 mM ZnSO 4 and 0.01% v/v Triton X-100) and buffer L2 (50 mM Tris pH 7.5, 10 mg.mL 21 BSA and 0.01% v/v Triton X-100). Reactions were carried out as described in (van Berkel et al., 2013) . For the chromogenic substrates meropenem, ceftazidime and aztreonam, substrate depletion was measured at 300 nm, 260 nm, 318 nm, respectively while for the fluorogenic substrate FC5, the excitation wavelength was set at 380 nm and emission wavelength at 460 nm (van Berkel et al., 2013) . Clavulanic acid was dissolved in double distilled water while avibactam and the bicyclic boronate 2 were dissolved in DMSO to prepare an appropriate stock solution. IC 50 values were calculated from reactions using FC5 (50 nM) as substrate for both L1 and L2 (used at 50 pM). Steady state kinetic data were analysed by curve fitting to the Michaelis-Menten equation using Prism software.
L2 crystallisation, data collection and structure modelling Initial L2 crystals grew using sitting-drop vapour diffusion in 96-well MRC 2-drop plates (molecular dimensions) with the Morpheus sparse matrix screen (Gorrec, 2009 ). Conditions were refined in CrysChem 24-well sitting-drop plates (Hampton Research, 188C), and diffraction-quality crystals were obtained by mixing 1 mL of L2 protein (42 mg.mL 21 ) with 1.5 mL reagent (10% w/v PEG 20000, 20% v/v PEG MME 550, 0.02 M DL-Glutamic acid; 0.02 M DL-Alanine; 0.02 M Glycine; 0.02 M DL-Lysine; 0.02 M DL-Serine, 0.1 M bicine/Trizma base pH 8.5) and equilibrated against 500 mL reagent. L2 complexes were obtained by soaking crystals in bicyclic boronate 2 (5 min, 2.5 mM) or avibactam (40 min, 5 mM) dissolved in reservoir reagent. L2 crystals were cryoprotected using reservoir solution plus 20% glycerol and flash frozen in liquid nitrogen. Crystallographic data were collected at 100K (I04-1, I04 or I03, Diamond Light Source, UK) and integrated in XDS (Kabsch, 2010) or DIALS (Waterman et al., 2016) , and scaled in Aimless in the CCP4 suite (Winn et al., 2011) . Phases were calculated by molecular replacement in Phaser (McCoy et al., 2007) using PDB 1O7E (unpublished) as a starting model. Avibactam and boronate structures, covalently bound to Ser70, and geometric restraints were generated using Phenix eLBOW (Moriarty et al., 2009) . Structures were completed by iterative rounds of manual model building in Coot (Emsley et al., 2010) and refinement in Phenix (Adams et al., 2010) . Structure validation was assisted by Molprobity and Phenix (Adams et al., 2010) . Figures were prepared using Pymol (Schrodinger).
NMR spectroscopy
The potential impact of avibactam or the bicyclic boronate 2 (both 75 lM) on the hydrolysis of meropenem (1 mM) by L1 (75 nM) was monitored over 20 min. The hydrolysis of avibactam (400 lM) and 2 (400 lM) by L1 (10 lM) was monitored over the course of 18 h or 24 h, respectively. All substrates, inhibitors and enzymes were prepared in 50 mM Tris-d 11 , pH 7.5, 10% D 2 O. Spectra were acquired on a Bruker AVIII 700 MHz spectrometer equipped with a 1 H/ 13 C/ 15 N TCI cryoprobe, and a Bruker AVIIIHD 600 MHz spectrometer equipped with a Prodigy broadband cryoprobe. 1 H spectra were acquired at 298 K using a 2 s relaxation delay, and were processed with a 0.3 Hz line broadening. The water signal was suppressed by excitation sculpting with perfect echo.
Data availability
Coordinates and structure factors for L2:native, L2:avibactam and L2:cyclic boronate 2 have been deposited in the Protein Data Bank under accession codes 5NE2, 5NE3 and 5NE1, respectively.
